Home > Insider Trading > Filing (0001209191-10-051872)

Filing Details

Accession Number:: 0001209191-10-051872
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-10-27 17:34:28
Reporting Period:: 2010-10-27

Filing Date:: 2010-10-27
Accepted Time:: 2010-10-27 17:34:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1034196	Advent International Corp/Ma	75 State Street, 29Th Floor Boston MA 02109		No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-10-27	1,263,312	$0.00	1,267,484	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2010-10-27	441,376	$0.00	1,708,860	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2010-10-27	814,092	$7.60	2,522,952	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2010-10-27	263,158	$9.50	2,786,110	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2010-10-27	3,264,283	$0.00	1,263,312	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-10-27	723,241	$0.00	441,376	$0.00
Common Stock	Senior Subordinated Convertible Promissory Notes	Disposition	2010-10-27	0	$0.00	814,092	$7.60

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Indirect
	No	4	C	Indirect
2011-12-31	No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,172	Indirect	See Footnote

Footnotes

These securities are indirectly beneficially owned in the following capacities; as Manager of Advent International LLC, which in turn is the General Partner of AHLS III GP, which in turn is the General Partner of Advent Healthcare & Life Sciences III Limited Partnership and Advent Healthcare & Life Science III A Limited Partnership. Advent International Corporation is also the General Partner of Advent Partners HLS III Limited Partnership.
Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share.
The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share.